Nestlé Uses AI to Design Nutrition for GLP-1 Users
New product line targets muscle loss and skin health side effects for patients using Ozempic and Wegovy.
A high-tech laboratory setting featuring a digital screen showing nutritional data and molecular structures, with modern product packaging nearby.
Photo: Kronos Digital News
Nestlé is using artificial intelligence and clinical research to develop a product line for GLP-1 weight-loss drug users [1][2]. The AI-driven approach identifies nutrient combinations to address side effects such as muscle loss during rapid weight reduction [1][3]. These products aim to support patients using medications like Ozempic and Wegovy [2].
The company is also focusing on "beauty-from-within" products to maintain skin health [3]. Research teams are leveraging nutritional science to fill dietary gaps caused by reduced appetite [1][2]. This initiative reflects a growing corporate focus on the metabolic health market [2].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
live.euronext.com
https://live.euronext.com/en/financial-news/nestle-looks-develop-new-products-serve-users-weight-loss-drugs
- 2.↗
outlookbusiness.com
https://www.outlookbusiness.com/corporate/nestle-eyes-new-product-line-to-serve-weight-loss-drug-users
- 3.↗
globalcosmeticsnews.com
https://www.globalcosmeticsnews.com/nestle-targets-glp-1-users-with-new-nutrition-and-beauty-from-within-products/
Related stories
View all
About the author
Kronos Digital News Desk covers news and editorial analysis for Kronos Digital News.